The importance of N6-methyladenosine modification in tumor immunity and immunotherapy

Abstract

As the most common and abundant RNA modification in eukaryotic cells, N6-methyladenosine (m6A) modification plays an important role in different stages of tumor. m6A can participate in the regulation of tumor immune escape, so as to enhance the monitoring of tumor by the immune system and reduce tumorgenesis. m6A can also affect the tumor progression by regulating the immune cell responses to tumor in tumor microenvironment. In addition, immunotherapy has become the most popular method for the treatment of cancer, in which targets such as immune checkpoints are also closely associated with m6A. This review discusses the roles of N6-methyladenosine modification in tumor immune regulation, their regulatory mechanism, and the prospect of immunotherapy. Graphical Abstract

Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma

“…Tumor-infiltrating immune cells are highly heterogeneous and have been shown to play important roles in immune evasion and the response to immunotherapy treatment ( 31 ). In the present study, the total macrophages from cancer and paracancer tissue were extracted, and they exhibited 12 distinct subclusters ( Figure 3A ), The tSNE plot shows the subcluster distribution among the sample pathology ( Figure 3B ).…”

ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner

“…For decades, an increasing number of studies have shown that m6A mRNA modification affects the biology of normal and tumor cells [ 31 – 34 ]. STM2457, a new bioavailable inhibitor of METTL3, was developed in 2021 as a new drug to treat myeloid leukemia [ 35 ].…”

The roles of RNA N6-methyladenosine in esophageal cancer

“…At present, immunotherapy has become the most popular cancer treatment method, among which targeting immune checkpoints is also closely related to m 6 A [ 96 ]. In the above, we discussed various mechanisms of immune evasion and immune regulation by m 6 A modification in cancer.…”

“…Inhibition of FTO can reduce tumor resistance to PD-1 treatment [ 88 ]. In addition to immunotherapy targeting PD-1, m6A modification is also involved in the regulation of cytotoxic T-lymphocyte antigen 4(CTLA-4) targeted therapy [ 96 ]. In addition, m 6 A modification has also been implicated in the regulation of TIM3 (T-cell immunoglobulin-3), TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains) and LAG3(Lymphocyte Activation Gene3) [ 96 ].…”

“…In addition to immunotherapy targeting PD-1, m6A modification is also involved in the regulation of cytotoxic T-lymphocyte antigen 4(CTLA-4) targeted therapy [ 96 ]. In addition, m 6 A modification has also been implicated in the regulation of TIM3 (T-cell immunoglobulin-3), TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains) and LAG3(Lymphocyte Activation Gene3) [ 96 ]. Although the relationship between these immune checkpoints and m 6 A has not been thoroughly studied, their potential impact on tumor immunotherapy should not be ignored.…”